relapsing polychondritis: Relapsing polychondritis (RP) is a rare, clinically heterogeneous, multisystemic inflammatory disease characterized by inflammation of the cartilage and proteoglycan rich structures leading to cartilage damage with joint, ocular and cardiovascular involvement.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
83 |
4. Check minimum number of eventsNone |
83 |
5. Include endpointsNone |
83 |
6. Filter based on genotype QC (FinnGen only) |
80 |
Control definitions (FinnGen only)
- Control exclude
- M13_OTHERBONE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M94
- Name in latin
- Polychondritis recidiva
Similar endpoints
↥List of similar endpoints to
Relapsing polychondritis
based on the number of shared cases.
Similar with more cases:
- Chondropathies
- Other disorders of bone
- Osteopathies and chondropathies
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 349 | 227 | 121 |
| Only index persons | 333 | 217 | 116 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 52.03 | 50.64 | 54.42 |
| Only index persons | 51.38 | 50.03 | 53.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 80 | 56 | 24 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 51.31 | 49.81 | 54.81 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 83
- Matched controls
- 830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M94.1
ICD-10 Finland
Relapsing polychondritis
+∞
119.5
83
*
L04AX03
ATC
methotrexate; systemic
23.8
49.9
51
52
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
16.1
37.2
45
57
H02AB06
ATC
prednisolone; systemic
8.4
15.6
68
292
L01BA01
ATC
methotrexate; systemic
18.7
12.0
18
12
H61.0
ICD-10 Finland
Perichondritis of external ear
+∞
11.7
11
*
L04AX01
ATC
azathioprine; systemic
19.0
11.4
17
11
P01BA02
ATC
hydroxychloroquine; oral
6.2
10.4
21
43
H02AB07
ATC
prednisone; oral
5.4
9.7
23
55
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.3
9.6
40
149
A46
ICD-10 Finland
Erysipelas
5.0
8.2
21
53
H62.0*A46
ICD-10 Finland
Otitis externa in erysipelas
49.9
7.9
9
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.1
7.4
18
31
J01FF01
ATC
clindamycin; systemic
3.5
7.0
36
150
R03BA05
ATC
fluticasone; inhalant
3.8
6.9
26
88
H60.1
ICD-10 Finland
Cellulitis of external ear
24.9
6.8
9
*
J01DB01
ATC
cefalexin; oral
9.8
6.8
80
607
J01FA06
ATC
roxithromycin; oral
3.3
6.6
49
252
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.2
6.5
42
199
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.8
6.4
16
39
M94.9
ICD-10 Finland
Disorder of cartilage, unspecified
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
345
3.67
6.83
5.0
3.5
0.00
0.00
estimate
-0.00
12
78
60
347
3.63
6.73
6.5
4.8
0.00
0.00
estimate
-0.00
12
75
60
350
3.58
6.57
5.0
3.5
0.00
0.00
estimate
-0.00
12
71
75
534
5.19
6.54
9.7
3.9
10.73
10.16
mm/h
0.16
75
486
15
24
7.38
6.53
1.7
1.5
—
—
—
0
0
33
150
2.99
5.30
1.6
1.3
10.40
39.19
iu/ml
—
10
48
11
16
7.74
5.14
1.5
1.3
—
—
—
0
0
9
10
9.92
4.92
1.2
1.2
—
—
—
0
0
9
10
9.92
4.92
1.2
1.2
—
—
—
0
0
9
10
9.92
4.92
1.2
1.2
—
—
—
0
0
9
10
9.92
4.92
1.2
1.2
—
—
—
0
0
9
10
9.92
4.92
1.2
1.2
—
—
—
0
0
11
21
5.86
4.32
1.3
1.0
—
—
—
0
0
49
298
2.57
4.24
5.4
5.4
1.21
1.22
mmol/l
0.23
43
250
8
11
7.91
3.96
1.1
1.2
—
—
—
0
0
34
182
2.47
3.76
2.8
2.5
0.15
0.42
e6/l
1.20
29
141
29
147
2.50
3.58
1.3
1.3
1.12
9.04
u/ml
1.65
13
59
38
223
2.30
3.35
3.3
2.8
—
—
—
0
0
18
80
2.60
2.85
2.2
1.7
—
—
—
0
0
28
153
2.25
2.85
2.6
1.7
0.49
1.32
mg/l
1.84
23
124
29
162
2.21
2.79
1.3
1.3
4.59
0.93
u/ml
—
9
45
5
6
8.76
2.78
1.0
1.5
—
—
—
0
0
5
6
8.76
2.78
1.2
1.0
—
—
—
0
0
43
282
2.09
2.73
5.3
3.5
—
—
—
0
0
9
26
3.75
2.57
8.2
8.5
23.67
24.30
mmol/l
—
9
26
37
236
2.02
2.48
3.0
3.1
33.35
32.19
u/l
0.10
37
222
15
67
2.51
2.34
6.2
6.0
105.73
103.79
mmol/l
0.84
15
67
32
197
2.02
2.34
6.2
3.7
0.00
0.00
estimate
-0.00
12
73
5
9
5.83
2.24
1.2
1.7
—
—
—
0
0
5
9
5.83
2.24
1.2
1.7
—
—
—
0
0
14
62
2.51
2.22
2.7
4.0
236.64
248.81
u/l
0.27
14
62
41
283
1.89
2.10
3.8
3.5
35.77
36.26
g/l
0.24
41
267
15
75
2.22
1.83
2.9
1.7
22.27
25.11
%
0.40
15
64
9
36
2.68
1.80
6.9
4.3
23.89
24.50
mmol/l
—
9
36
41
295
1.77
1.76
23.2
10.0
1.32
1.15
inr
0.61
19
91
8
31
2.74
1.71
1.8
2.4
1.04
1.51
%
—
8
31
6
20
3.15
1.61
1.3
1.8
—
—
—
0
0
11
51
2.33
1.58
2.6
1.6
—
—
—
0
0
18
103
1.95
1.56
2.7
2.3
0.85
0.84
e6/l
—
10
63
7
27
2.73
1.55
1.1
1.4
—
—
—
0
0
22
136
1.84
1.52
1.7
1.5
—
—
—
0
0
7
28
2.63
1.49
1.9
1.4
—
—
—
0
0
10
46
2.33
1.46
7.6
5.3
0.99
1.36
mmol/l
—
10
46
6
22
2.86
1.46
1.3
2.0
—
—
—
0
0
16
90
1.96
1.45
2.6
2.6
0.81
3.51
e6/l
—
8
51
9
40
2.40
1.45
1.4
1.5
—
—
—
0
0
19
115
1.85
1.40
4.5
3.1
182.00
167.84
ng/l
—
8
79
11
55
2.15
1.34
2.6
1.5
—
—
—
0
0
11
55
2.15
1.34
1.2
1.2
45.87
143.88
iu/ml
—
6
20
40
302
1.63
1.34
4.3
2.6
123.44
101.56
ug/l
0.36
40
282
50
402
1.61
1.28
4.0
3.9
6.21
6.61
mmol/l
1.07
50
376
40
306
1.59
1.25
2.0
2.4
—
—
—
0
0
16
95
1.85
1.25
3.8
1.7
11.99
14.46
umol/l
0.88
16
85
5
20
2.59
1.17
1.6
1.4
—
—
—
0
0
21
139
1.68
1.15
1.9
2.2
—
—
—
0
0
32
238
1.56
1.10
2.0
1.9
92.21
95.78
pmol/l
0.17
20
128
33
249
1.54
1.06
4.4
3.7
17.57
45.94
ng/l
1.02
21
159
13
78
1.79
0.98
3.5
2.1
286.31
358.76
nmol/l
0.66
13
71
70
630
1.71
0.96
32.6
14.2
14.38
14.90
%
0.57
70
619
0
25
0.00
0.80
0.0
2.2
—
2.63
—
0
20
5
23
2.25
0.77
1.4
1.1
—
—
—
0
0
5
24
2.15
0.76
1.0
1.9
—
—
—
0
0
5
26
1.98
0.72
3.6
3.4
24.68
24.75
mmol/l
—
5
26
5
26
1.98
0.72
2.6
1.5
—
—
—
0
0
7
44
1.64
0.67
1.0
1.1
—
—
—
0
0
10
67
1.56
0.52
3.4
3.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
1.10
—
0
16
0
17
0.00
0.41
0.0
1.6
—
24.96
—
0
17
53
485
1.26
0.40
3.6
3.2
—
—
—
0
0
6
43
1.43
0.36
1.7
1.2
—
—
—
0
0
11
138
0.77
0.28
1.7
1.7
474.82
483.59
pmol/l
0.05
11
119
9
75
1.22
0.26
3.3
2.7
6.87
7.88
umol/l
—
9
64
10
78
1.32
0.25
4.0
6.1
—
—
—
0
0
10
79
1.30
0.23
3.3
2.9
0.95
1.01
mmol/l
—
10
74
11
89
1.27
0.22
2.3
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
11
100
1.12
0.05
2.5
2.1
—
—
—
0
0
14
150
0.92
0.04
1.3
1.4
—
—
—
0
0
56
549
1.06
0.04
5.9
4.3
14.75
14.62
pmol/l
0.13
56
513
17
177
0.95
0.01
6.4
5.1
1.93
1.82
ug/l
0.06
17
161
14
141
0.99
0.00
5.1
4.4
24.52
20.80
%
—
6
64
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
70
700
1.00
-0.00
3.7
4.5
1.53
1.50
mmol/l
0.20
70
647
0
9
0.00
-0.00
0.0
5.7
—
127.19
—
0
9
9
89
1.01
-0.00
1.4
1.7
1.30
1.35
%
—
9
77
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
56.80
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
65
0.92
-0.00
2.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_RELAPSPOLYCHONDR and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have M13_RELAPSPOLYCHONDR.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: M13_RELAPSPOLYCHONDR – Relapsing polychondritis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data